• Je něco špatně v tomto záznamu ?

Prevention of Vitamin K Deficiency Bleeding in Newborn Infants: A Position Paper by the ESPGHAN Committee on Nutrition

WA. Mihatsch, C. Braegger, J. Bronsky, C. Campoy, M. Domellöf, M. Fewtrell, NF. Mis, I. Hojsak, J. Hulst, F. Indrio, A. Lapillonne, C. Mlgaard, N. Embleton, J. van Goudoever, . ,

. 2016 ; 63 (1) : 123-9.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, směrnice pro lékařskou praxi

Perzistentní odkaz   https://www.medvik.cz/link/bmc18011269

Vitamin K deficiency bleeding (VKDB) due to physiologically low vitamin K plasma concentrations is a serious risk for newborn and young infants and can be largely prevented by adequate vitamin K supplementation. The aim of this position paper is to define the condition, describe the prevalence, discuss current prophylaxis practices and outcomes, and to provide recommendations for the prevention of VKDB in healthy term newborns and infants. All newborn infants should receive vitamin K prophylaxis and the date, dose, and mode of administration should be documented. Parental refusal of vitamin K prophylaxis after adequate information is provided should be recorded especially because of the risk of late VKDB. Healthy newborn infants should either receive 1 mg of vitamin K1 by intramuscular injection at birth; or 3 × 2 mg vitamin K1 orally at birth, at 4 to 6 days and at 4 to 6 weeks; or 2 mg vitamin K1 orally at birth, and a weekly dose of 1 mg orally for 3 months. Intramuscular application is the preferred route for efficiency and reliability of administration. The success of an oral policy depends on compliance with the protocol and this may vary between populations and healthcare settings. If the infant vomits or regurgitates the formulation within 1 hour of administration, repeating the oral dose may be appropriate. The oral route is not appropriate for preterm infants and for newborns who have cholestasis or impaired intestinal absorption or are too unwell to take oral vitamin K1, or those whose mothers have taken medications that interfere with vitamin K metabolism. Parents who receive prenatal education about the importance of vitamin K prophylaxis may be more likely to comply with local procedures.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011269
003      
CZ-PrNML
005      
20180404142704.0
007      
ta
008      
180404s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MPG.0000000000001232 $2 doi
035    __
$a (PubMed)27050049
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mihatsch, Walter A $u *Department of Pediatrics, Harlaching, Munich Municipal Hospitals, Munich, Germany†Department of Pediatric Gastroenterology, University Children's Hospital, Zurich, Switzerland‡Department Pediatrics, University Hospital Motol, Prague, Czech Republic§Department of Pediatrics, University of Granada, Granada, Spain||Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden¶Childhood Nutrition Research Centre, UCL Institute of Child Health, London, UK#Department of Gastroenterology, Hepatology and Nutrition, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia**University Children's Hospital Zagreb, Zagreb, Croatia††Department of Pediatrics, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands‡‡Department of Pediatrics, University Hospital Giovanni XXIII, University Aldo Moro, Bari, Italy§§APHP Necker-Enfants Malades Hospital, Paris Descartes University, Paris, France||||CNRC, Baylor College of Medicine, Houston, TX¶¶Department of Nutrition, Exercise and Sports, University of Copenhagen, K⊘benhavn##Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark***Newcastle Neonatal Service, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK†††Department of Pediatrics, VU University Medical Center‡‡‡Department of Pediatrics, Emma Children's Hospital-AMC, Amsterdam, The Netherlands.
245    10
$a Prevention of Vitamin K Deficiency Bleeding in Newborn Infants: A Position Paper by the ESPGHAN Committee on Nutrition / $c WA. Mihatsch, C. Braegger, J. Bronsky, C. Campoy, M. Domellöf, M. Fewtrell, NF. Mis, I. Hojsak, J. Hulst, F. Indrio, A. Lapillonne, C. Mlgaard, N. Embleton, J. van Goudoever, . ,
520    9_
$a Vitamin K deficiency bleeding (VKDB) due to physiologically low vitamin K plasma concentrations is a serious risk for newborn and young infants and can be largely prevented by adequate vitamin K supplementation. The aim of this position paper is to define the condition, describe the prevalence, discuss current prophylaxis practices and outcomes, and to provide recommendations for the prevention of VKDB in healthy term newborns and infants. All newborn infants should receive vitamin K prophylaxis and the date, dose, and mode of administration should be documented. Parental refusal of vitamin K prophylaxis after adequate information is provided should be recorded especially because of the risk of late VKDB. Healthy newborn infants should either receive 1 mg of vitamin K1 by intramuscular injection at birth; or 3 × 2 mg vitamin K1 orally at birth, at 4 to 6 days and at 4 to 6 weeks; or 2 mg vitamin K1 orally at birth, and a weekly dose of 1 mg orally for 3 months. Intramuscular application is the preferred route for efficiency and reliability of administration. The success of an oral policy depends on compliance with the protocol and this may vary between populations and healthcare settings. If the infant vomits or regurgitates the formulation within 1 hour of administration, repeating the oral dose may be appropriate. The oral route is not appropriate for preterm infants and for newborns who have cholestasis or impaired intestinal absorption or are too unwell to take oral vitamin K1, or those whose mothers have taken medications that interfere with vitamin K metabolism. Parents who receive prenatal education about the importance of vitamin K prophylaxis may be more likely to comply with local procedures.
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a Evropa $7 D005060
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a fyziologie výživy kojenců $7 D007227
650    _2
$a novorozenec $7 D007231
650    _2
$a injekce intramuskulární $7 D007273
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a společnosti lékařské $7 D012955
650    _2
$a vitamin K $x aplikace a dávkování $x terapeutické užití $7 D014812
650    _2
$a krvácení z nedostatku vitaminu K $x prevence a kontrola $7 D006475
655    _2
$a časopisecké články $7 D016428
655    _2
$a směrnice pro lékařskou praxi $7 D017065
700    1_
$a Braegger, Christian
700    1_
$a Bronsky, Jiri
700    1_
$a Campoy, Cristina
700    1_
$a Domellöf, Magnus
700    1_
$a Fewtrell, Mary
700    1_
$a Mis, Nataša F
700    1_
$a Hojsak, Iva
700    1_
$a Hulst, Jessie
700    1_
$a Indrio, Flavia
700    1_
$a Lapillonne, Alexandre
700    1_
$a Mlgaard, Christian
700    1_
$a Embleton, Nicholas
700    1_
$a van Goudoever, Johannes
700    1_
$a ,
773    0_
$w MED00010080 $t Journal of pediatric gastroenterology and nutrition $x 1536-4801 $g Roč. 63, č. 1 (2016), s. 123-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27050049 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180404142744 $b ABA008
999    __
$a ok $b bmc $g 1288754 $s 1008081
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 63 $c 1 $d 123-9 $i 1536-4801 $m Journal of pediatric gastroenterology and nutrition $n J Pediatr Gastroenterol Nutr $x MED00010080
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...